Through its academic collaborations, BridgeBio seeks to revolutionize the relationships between the drug development industry and biomedical researchers by moving away from one-off interactions in favor of engaging and creative partnerships. For a list of some of BridgeBio's academic partners, please visit Our Partners page. About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.